Skip to main content
Livermore
Livermore
ZHEN

JNE Partners LLP

SEC CIK
0001770120
Latest filing
Aug 14, 2026

The latest 13F from JNE Partners LLP covers Q2 2026 (filed Aug 14, 2026): 6 long positions worth $243.2M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Liberty Live Holdings, Inc. (LLYVK) at 51.0%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
0
Reduced
1
Est. −$1.05M
Sold out
1
Est. −$278.7K

Top 5 holdings

Share of this quarter's portfolio value

  1. LLYVKLiberty Live Holdings, Inc.
    51.0%$123.9MHistory
  2. LLYVALiberty Live Holdings, Inc.
    15.3%$37.3MHistory
  3. NIQNIQ Global Intelligence plc
    14.3%$34.9MHistory
  4. BIOBio-Rad Laboratories, Inc.
    10.7%$26.0MHistory
  5. LBRDALiberty Broadband Corp
    8.7%$21.1MHistory

Biggest buys

New and added positions, by estimated amount bought

None this quarter.

Largest weight increases

New and added positions, by percentage points of the portfolio gained

None this quarter.

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. BIOBio-Rad Laboratories, Inc.
    −$1.05MReducedHistory
  2. LBRDKLiberty Broadband Corp
    −$278.7KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. LBRDKLiberty Broadband Corp
    −0.11 pp0.1% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$243.2M
−$1.19M (−0.5%) vs. prior quarter
Positions
6
−1 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q2 2026, one quarter
Average holding period
3.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $248.7M (Q2 2025)

Q1 2021: $128.6MQ2 2021: $136.3MQ3 2021: $177.3MQ4 2021: $152.6MQ1 2022: $211.2MQ2 2022: $153.1MQ3 2022: $172.8MQ4 2022: $144.5MQ1 2023: $132.2MQ2 2023: $57.5MQ3 2023: $85.5MQ4 2023: $87.1MQ1 2024: $68.9MQ2 2024: $65.7MQ3 2024: $86.1MQ4 2024: $168.4MQ1 2025: $192.0MQ2 2025: $248.7MQ3 2025: $234.9MQ4 2025: $240.7MQ1 2026: $244.4MQ2 2026: $243.2M
Q1 2021Q2 2026
13F filings of JNE Partners LLP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20266$243.2MLLYVKLLYVANIQvs. Q1 2026SEC
Q1 2026May 15, 20267$244.4MLLYVKNIQLLYVAvs. Q4 2025SEC
Q4 2025Feb 17, 20267$240.7MLLYVKNIQLBRDAvs. Q3 2025SEC
Q3 2025Nov 14, 20258$234.9MLLYVKLBRDALLYVAvs. Q2 2025SEC
Q2 2025Aug 14, 20258$248.7MLLYVKLBRDABATRKvs. Q1 2025SEC
Q1 2025May 15, 20257$192.0MLLYVKLBRDABATRKvs. Q4 2024SEC
Q4 2024Feb 14, 20257$168.4MLLYVKLBRDABATRKvs. Q3 2024SEC
Q3 2024Nov 14, 20244$86.1MLLYVKBATRKNGvs. Q2 2024SEC
Q2 2024Aug 14, 20244$65.7MLLYVKBATRKNGvs. Q1 2024SEC
Q1 2024May 15, 20244$68.9MLLYVKBATRKNGvs. Q4 2023SEC
Q4 2023Feb 14, 20245$87.1MLLYVKBATRKMUvs. Q3 2023SEC
Q3 2023Nov 14, 20235$85.5MMULLYVKBATRKvs. Q2 2023SEC
Q2 2023Aug 14, 20235$57.5MMUElliott Opportunity II Corp.BATRKvs. Q1 2023SEC
Q1 2023May 15, 20237$132.2MATVIMUOrion Biotech Opportuntes Covs. Q4 2022SEC
Q4 2022Feb 14, 20239$144.5MATVIMUMSD Acquisition Corp.vs. Q3 2022SEC
Q3 2022Nov 14, 202213$172.8MATVIMUNSITvs. Q2 2022SEC
Q2 2022Aug 15, 202214$153.1MATVINSITMSD Acquisition Corp.vs. Q1 2022SEC
Q1 2022May 16, 202215$211.2MATVICMCSACPvs. Q4 2021SEC
Q4 2021Feb 15, 202213$152.6MCMCSACPBABAvs. Q3 2021SEC
Q3 2021Nov 15, 202113$177.3MUHALCMCSACPvs. Q2 2021SEC
Q2 2021Aug 12, 202111$136.3MCMCSAUHALNGvs. Q1 2021SEC
Q1 2021May 17, 20218$128.6MUHALCMCSANG–SEC

13D and 13G filings

Companies where JNE Partners LLP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where JNE Partners LLP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
Cool Co Ltd.Common Stock, par value $1.00 per share13G5.12%2.71M sharesNewOct 28, 20251 filingOct 28, 2025SEC

Latest filings

2 filings on file made by JNE Partners LLP or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by JNE Partners LLP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
Cool Co Ltd.Common Stock, par value $1.00 per shareOct 28, 20259:36 PM ET13G5.12%2.71M sharesNewOct 21, 2025SEC
Prevail Therapeutics Inc.Jan 29, 202113GOld format–New–SEC